Michael Cloonan
Directeur/Membre du Conseil chez BLUEBIRD BIO, INC.
Profil
Michael Cloonan est directeur de l'exploitation de SAGE Therapeutics, Inc. Dans le passé, il a occupé le poste de Senior Vice President-US Commercial chez Biogen, Inc. M. Cloonan a obtenu un MBA à la Darden School of Business de l'Université de Virginie et un diplôme de premier cycle au College of the Holy Cross (Massachusetts).
Postes actifs de Michael Cloonan
| Sociétés | Poste | Début |
|---|---|---|
| BLUEBIRD BIO, INC. | Directeur/Membre du Conseil | 20/06/2024 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Consultant / Advisor | - |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Directeur Général | - |
Anciens postes connus de Michael Cloonan
| Sociétés | Poste | Fin |
|---|---|---|
| SAGE THERAPEUTICS, INC. | Directeur des opérations | 03/05/2021 |
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2017 |
Formation de Michael Cloonan
| University of Virginia Darden School of Business | Masters Business Admin |
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SAGE THERAPEUTICS, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| BLUEBIRD BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Health Services |
